NURITAS
Dublin, IE · Founded 2014 · 70 employees on LinkedIn · 16 known investors
Nuritas uses a proprietary AI platform, the Nuritas Magnifier, to discover and clinically validate bioactive peptide ingredients derived from natural sources. It develops formulation-ready ingredients such as PeptiStrong for food, supplement, and health product companies.
Also known as Nuritas Limited · Nuritas™
Founders & leadership
NURITAS was founded in 2014 by Dr. Nora Khaldi.
Investors · 16
Also in the syndicate · 9
Company profile
researched Aug 2026Nuritas is a Dublin, Ireland-based biotechnology company that discovers and develops bioactive peptides — short protein fragments — from plants and other natural food sources, and supplies them as formulation-ready ingredients to consumer product companies. Its proprietary AI platform, referred to as the Nuritas Magnifier (earlier described as Nπϕ, the Nuritas Peptide Finder), combines artificial intelligence, deep learning and genomics to screen billions of candidate peptides and predict which ones act on specific health areas, molecular pathways or receptors. Candidates are then taken through preclinical and human clinical studies, with results published in peer-reviewed journals.
The commercial portfolio is organised around branded ingredients addressing muscle health, sleep and skin. PeptiStrong, derived from fava bean (Vicia faba) protein, is a network of cell-signalling peptides positioned for muscle strength, recovery and energy; the company cites clinical results including a 17% increase in strength versus placebo, 144% increase in strength recovery, 54% increase in muscle energy and 47% less muscle fatigue, delivered as a neutral, odourless 2.4g powder dose formulated into powders, bars, shakes, capsules, chewable tablets, gels, gummies, clear beverages and shots. It has self-affirmed/FDA GRAS status in the U.S. and is registered with Health Canada. PeptiYouth, targeting wrinkle depth reduction via collagen production, is used in skin-care products in the U.S. and Asia, and PeptiSleep addresses sleep. Earlier work included PeptAide 4, described as the first AI-discovered ingredient in rice, developed with BASF.
The company states it has identified a library of more than eight million natural peptides with known functionalities, claims an 80%-plus success rate translating peptides from in vitro to clinical efficacy, and reports 56 issued patents. It says its peptides appear in more than 100 products worldwide, with over 200 million doses served.
Founding story
Nuritas was founded in Dublin in 2014 by Dr. Nora Khaldi, a mathematician with a Ph.D. in molecular evolution and bioinformatics, on the premise that AI could reveal health-relevant peptides hidden in nature. The company frames the problem as scale: over a billion potential peptides exist in plants alone, and conventional one-by-one testing takes decades and costs hundreds of millions, while consumer trust in brand health claims is low.
Business model
Business-to-business ingredient supplier: Nuritas discovers, patents, clinically validates and manufactures branded peptide ingredients that food, beverage, supplement and cosmetics companies license and formulate into their own finished products. It also offers custom peptide discovery partnerships in which its AI platform is applied to a partner's specified health outcome.
Revenue is generated from sales and supply of branded, ready-to-use peptide ingredients (such as PeptiStrong, PeptiSleep and PeptiYouth) to brand and formulator customers, and from partnership-based custom discovery programmes with corporate partners.
Traction
The company reports its SmartPeptides are used in more than 100 products worldwide with over 200 million doses supplied to date, 56 issued patents, three human clinical trials on PeptiStrong including a randomised, double-blind, placebo-controlled study published in BMJ Nutrition, Prevention & Health (2025), and a peer-reviewed PeptiSleep sleep study in Sleep Medicine: X. A retailer report cited by the company noted branded ingredient searches for PeptiStrong up 400%. Total funding to date was stated at $75 million at the November 2021 Series B, followed by a $42 million Series C announced in December 2024.
Latest developments
Following the oversubscribed $42 million Series C led by M&G Investments' Catalyst strategy with McWin Capital Partners and existing investors Grosvenor and ECBF, Nuritas added Alex Seddon (M&G) and Henry McGovern (McWin) to its board and said it planned to introduce three new clinically validated peptide ingredients in 2025. Subsequent company news includes publication of a peer-reviewed PeptiSleep study in Sleep Medicine: X (August 2026), the UK's first ginger and turmeric PeptiStrong shot launched by Good Shots (June 2026), and a reported 400% rise in branded ingredient searches for PeptiStrong in The Vitamin Shoppe's 2026 Health & Wellness Report.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Nuritas positions itself as a science-led leader in AI-discovered peptide ingredients, claiming the world's largest peptide knowledge base and a portfolio of 56 clinically-proven patented peptides spanning strength, energy and recovery, collagen production, sleep and metabolism, contrasted with traditional ingredient discovery that it describes as taking decades and costing tens to hundreds of millions.
Differentiation rests on the AI-driven discovery platform's claimed speed (10-50x faster than conventional methods) and clinical success rate (over 80% versus what the company describes as low single-digit industry norms), an in-house library of more than eight million functionally annotated natural peptides, an issued patent estate of 56 patents, and human clinical trials published in peer-reviewed journals supporting each commercial ingredient.
Technology
The Nuritas Magnifier platform applies artificial intelligence, deep learning and genomics to screen billions of peptides present in plants and natural food sources, predicting activity against specific molecular pathways and receptors before laboratory and clinical validation. The company reports identifying peptides 10-50 times faster than traditional methods, a library of over 8 million peptides with known functionalities, and a clinical translation success rate above 80%. Mechanistic claims for PeptiStrong include action via mTOR and phospho-S6 pathways to raise muscle protein synthesis, reduced breakdown via Atrogin and MuRF1, increased mitochondrial mass, and suppressed plasma myostatin.
Go-to-market
Nuritas sells through B2B channels, supplying clinically substantiated branded ingredients with supporting peer-reviewed studies and regulatory clearances (GRAS in the U.S., Health Canada registration, non-novel food status) to brand owners, and offering sample requests and co-development partnerships. Finished products containing its ingredients reach consumers via pharmacies, retail outlets, online platforms and specialty stores across multiple continents.
Consumer-goods and ingredient companies — functional food and beverage brands, dietary supplement and sports nutrition makers, medical food companies, cosmetics/skin-care brands and food technology firms — plus formulators and researchers. Named partners and customers include Givaudan, Nestlé, Mars, Sumitomo Corporation, Pharmavite and BASF, with finished-product examples from Good Shots, Syform, Biogena, Unmatched, Ultra Labs and Terravita.
Geography
Headquartered in Dublin, Ireland, where it operates a research facility. Ingredients are commercialised in the U.S., Canada, the UK, Europe and Asia, and 2021 funding was earmarked in part for building a U.S. headquarters.
History
Founded in Dublin in 2014, Nuritas built the first version of its AI platform between 2015 and 2017, when initial AI-identified peptides were validated preclinically and Bono, The Edge and Marc Benioff invested. From 2018 to 2020 the company identified PeptiStrong (fava bean) and PeptiYouth candidates, began human clinical trials and published its first peer-reviewed papers. In 2021 it introduced PeptAide 4, an AI-discovered rice ingredient developed with BASF, launched PeptiYouth and PeptiStrong for early 2022 market entry, and closed a $45 million Series B. Between 2021 and 2024 PeptiStrong, PeptiSleep and PeptiYouth were commercially launched, global brand partnerships were signed and 56 patents were issued. A $42 million Series C closed in December 2024, and in 2025-2026 the company published a randomised controlled PeptiStrong trial in BMJ Nutrition, Prevention & Health and reported its peptides in more than 100 products globally.
Risks & controversies
Efficacy figures for PeptiStrong and other ingredients are largely drawn from company-cited studies and company-reported metrics; the company itself notes that two-thirds of consumers do not trust brand health claims, and its product pages state that labelling and permissible claims vary by jurisdiction, indicating regulatory dependence across markets.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 1
by search overlap
Companies competing with NURITAS for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 12
launches, deals, and filingsA randomised, double-blind, placebo-controlled study of PeptiStrong was published in BMJ Nutrition, Prevention & Health (2025;:bmjnph-2024-001050).
Series C led by M&G Investments on behalf of its Catalyst strategy, with McWin Capital Partners joining and existing investors Grosvenor and ECBF participating; proceeds allocated to scaling operations and global customer expansion.
$42M source ↗
As part of the Series C, Alex Seddon (Head of Impact & Private Equity, M&G Investments) and Henry McGovern (co-founder, McWin Capital Partners) joined Nuritas' Board of Directors.
Nuritas reports high-profile partnerships with Givaudan, Nestlé, Mars and Sumitomo Corporation spanning functional foods, dietary supplements, medical foods, cosmetics and food technology.
PeptiStrong, Nuritas' patented fava bean-derived flagship peptide ingredient, achieved FDA-approved GRAS (Generally Recognized as Safe) status in the United States.
Nuritas launched PeptiYouth, a peptide that reduces wrinkle depth by promoting collagen production, featured in skin-care products in the U.S. and Asia.
Series B led by Cleveland Avenue, LLC with Grosvenor's Wheatsheaf Group, ECBF, Vertex Holdings, Nutresa Ventures/Veronorte, CJ, Cultivian Sandbox Ventures and VisVires New Protein; funds directed to a US headquarters, team growth and platform scaling. Total funding to date stated at $75 million.
$45M source ↗
Randall Lewis (Cleveland Avenue) and Stephan Dolezalek (Grosvenor's Wheatsheaf Group) joined the Board of Directors; Indra Nooyi, Joerg Ohle and Bruce German joined the Advisory Board.
Two clinically proven ingredients were launched: PeptiYouth, discovered from peas and supporting skin health, and PeptiStrong, discovered in fava beans and supporting muscle health, both being formulated for early 2022 market entry.
Nuritas introduced PeptAide 4, described as the world's first AI-discovered ingredient in rice, developed together with BASF.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- NURITASnuritas.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does NURITAS do?
- Nuritas is a Dublin-based B2B company using an AI platform to discover and clinically validate bioactive peptide ingredients.
- Who founded NURITAS?
- NURITAS was founded by Dr. Nora Khaldi in 2014.
- Who are NURITAS's investors?
- NURITAS's investors include Cleveland Avenue, McWin Capital Partners, Marc Benioff, European Circular Bioeconomy Fund, Keiretsu Forum, Cultivian Sandbox Ventures, Sandbox Industries.
- Where is NURITAS headquartered?
- NURITAS is headquartered in Dublin, IE.